Dear H, do you have any pull to see if VRTX will consider running a pilot study for PCD ( primary ciliary dyskinesia) with Ivacaftor and see if it will work for this orphan indication? Approximately 25 K patients have this disease in US and consequences are same like CF. It is all about phenotype and I fully understand pathology is totally different in PCD. If it turns out to be positive, label expansion will be huge.
I don't think any body understand what ATR inhibitor VX 970 is? PYCY BTK inhibitor is nothing in front of this ALT cancer cells killer. AZN has AZ 20 in phase 1 as a competition.
andexanet alfa last week got orphan status i.e market exclusivity for 7 years as a factor X a inhibitor. It has to get approval by FDA before PER977 to get this reward. I agree with the Internal Medicine physician that Betrixaban will be a big hospital and out patient drug and it is very likley that MRK will come back and write a 5 B check to PTLA.
EIP pharma has licensed this drug from VRTX and they are starting a phase 2 a trial in VU medical CTR in Amsterdam. Does any one remembers or knows VRTX deal with EIP? Drug basis for AD look very attractive.
I think Cethrin is very exciting for acute SCI. C5 level is the most common after MVA and data in 40 patient study published in Journal of Neurotrauma with C4-C7 is very interesting. Combining Cethrin with Acorda or NVS drug will not be a bad idea.
same people who are willing to pay for 6" of improvement. Have you every watch " Cialis" ad before the nightly news? Something is good about the word " six".
unfortunately they don't believe in science. same guy brought VRTX to $66 last year after CF conference in Europe. Bipolar disorder.
VRTX is not for sale. It carries a value way higher than $180. Cethrin data for Acute SCI is pointing in positive direction for C4-C7 injury. VX 787 phase II b will be out any day and it should be positive ( protease inhibitors carries a long success story in HIV and Hep C) to move into phase III next winter. VX 970( Avastin of VRTX) preliminary results 06/2015. Dr. David Altshuler is going to bring lot of innovative and transformational work in VRTX in coming years.
This drug needs a proper proof of concept in resistant epilepsy at 600 mg and 900 mg dose. I think neurology academia is looking towards VRTX. Preclinical data is too strong to ignore that this drug has a strong role in epilepsy. Studies were discontinued prematurely after 40 patients in phase II b due to cost issues and pipe line prioritization ( Hep C disaster). This transformational medicine and first in class. My hope is this will lead to a anoxic brain injury drug in a cardiac arrest patient, an unmet and sad clinical scenario, where inflammation from anoxia causes cell death followed by brain edema and further cuts off brain circulation.
EIP pharmaceutical has started couple of phase II studies of VX 745 in AD including a dynamic quantitative PET scan study measuring amyloid plaque. This is going on under the analysts radar.
INCY gained 6 B from Baricitinib for RA and VX 509 is dead despite of a positive phase II B study in RA two years ago.